Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Adam W Mailloux, ^a   Epling Burnette, Pearlie K ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immune escape; Immunoediting; Leukemia; Myelodysplastic syndrome; Regulatory T cells

Indexed keywords

GAMMA INTERFERON;

CANCER RISK; CANCER SURVIVAL; CELL EXPANSION; CLINICAL FEATURE; CROSS REACTION; CYTOKINE PRODUCTION; DISEASE COURSE; EFFECTOR CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOEDITING; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LEUKEMIA; MALIGNANT TRANSFORMATION; MEMORY T LYMPHOCYTE; MYELODYSPLASTIC SYNDROME; NONHUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE;

EID: 84886945336     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22654     Document Type: Note

References (10)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; PMID:15308095; http://dx.doi.org/10.1016/j.immuni.2004.07.017.
2. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628-36; PMID:16179369; http://dx.doi.org/10.1182/blood-2005-07-2737.
3. Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 2009; 16:70-6; PMID:19468267; http://dx.doi.org/10.1097/MOH.0b013e3283257ac7.
4. Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol 2011; 38:667-72; PMID:21943673; http://dx.doi.org/10.1053/j.seminoncol.2011.04.006.
5. Sloand EM, Barrett AJ. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. Hematol Oncol Clin North Am 2010; 24:331-41; PMID:20359629; http://dx.doi.org/10.1016/j.hoc.2010.02.009.
6. Sloand EM, Melenhorst JJ, Tucker ZC, Pfannes L, Brenchley JM, Yong A, et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011; 117:2691-9; PMID:21097671; http://dx.doi.org/10.1182/blood-2010-04-277921.
7. Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113:1351-61; PMID:18618511; http://dx.doi.org/10.1002/cncr.23697.
8. Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011; 118:5084-95; PMID:21881045; http://dx.doi.org/10.1182/blood-2011-07-365817.
9. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110:847-50; PMID:17412885; http://dx.doi.org/10.1182/blood-2007-01-067546.
10. Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol 2012; 189:3198-208; PMID:22875800; http://dx.doi.org/10.4049/jimmunol.1200602.